Pfizer (PFE) and other drugmakers met with the Trump administration to discuss lowering U.S. drug prices but no commitments have been made, Pfizer CEO Albert Bourla said on Monday at the Goldman Sachs Healthcare Conference. Boula said the meetings “were cordial,” but they were not “digging into the substance yet,” adding that “it is just trying to understand high-level ideas and no commitments. So what could be the outcomes of something like that? It could be from nothing to very big.””

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions

• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on PFE:

Disclaimer & DisclosureReport an Issue

• RFK Jr. reconstituting vaccine advisory committee, retiring 17 current members

• RFK Jr. removes members of vaccine-advising CDC panel, CNBC reports

• Morning News Wrap-Up: Monday’s Biggest Stock Market Stories

• Pfizer (PFE) Faces Tough Choices as Trump Targets U.S. Drug Prices

• Pfizer call volume above normal and directionally bullish